---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-006614"
form_type: "8-K/A"
ticker: "RNTX"
cik: "0001420565"
company_name: "Rein Therapeutics, Inc."
filed_at: "2024-01-11T23:59:59+00:00"
generated_at: "2026-06-07T00:31:13.261014+00:00"
event_type: "m_and_a"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Aileron provides Lung Therapeutics financials: net loss $19M in 2022, accumulated deficit $63M, going concern cited

## Summary
- Lung Therapeutics net loss $19.0M in 2022, $9.9M in 2021; cash and equivalents $11.9M at Dec 31, 2022.
- Accumulated deficit $63.4M; auditor's report includes substantial doubt about going concern.
- Lung's lead candidate LTI-03 (IPF) in Phase 1b; LTI-01 (LPE) completed Phase 2.
- Pro forma condensed combined financial statements also filed with this 8-K/A.

## SEC filing metadata
- accession: 0001193125-24-006614
- form_type: 8-K/A
- ticker: RNTX
- cik: 0001420565
- company_name: Rein Therapeutics, Inc.
- filed_at: 2024-01-11T23:59:59+00:00
- event_type: m_and_a
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1420565/000119312524006614/0001193125-24-006614-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1420565/000119312524006614/d22567d8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-006614
- JSON: https://secwatch.observer/filing/0001193125-24-006614.json
- Plain text: https://secwatch.observer/filing/0001193125-24-006614.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.